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This article deals with the prevalence and the possible reasons of COPD underestimation in the population and
gives suggestions on how to overcome the obstacles and make the correct diagnosis in order to provide the
patients with the appropriate therapy. COPD is diagnosed in later or very advanced stages. In Italy the rate of COPD
under-diagnosis ranges between 25 and 50% and, as a consequence, the patient does not consult his doctor until
the symptoms have worsened, mainly due to exacerbations. A missed diagnosis influences the timing of therapeutic
intervention, thus contributing to the evolution into more severe stages of the illness. An incisive intervention to limit
under-diagnosis cannot act only in remittance (passive diagnosis), but must be the promoter for a series of preventive
actions: primary, secondary and rehabilitative. To reduce under-diagnosis, some actions need to be taken, such as
screening programs for smokers subjects, use of questionnaires aimed to qualify and monitor the disease severity,
spirometry, early diagnosis. There is a consensus regarding diagnoses based on screening of at-risk subjects and
symptoms, rather than screening of the general population. In practice, all individuals over 40 years of age with risk
factors should make a spirometry test. Screening actions on a national scale can be the following: compilation of
questionnaires in waiting rooms of doctor’s offices or performing simple maneuvers to evaluate the expiratory
force at pharmacies. It is now widely recognized that COPD is a complex syndrome with several pulmonary and
extrapulmonary components; as a result, the airway obstruction as assessed by FEV1 by itself does not adequately
describe the complexity of the disease and FEV1 cannot be used alone for the optimal diagnosis, assessment, and
management of the disease. The identification and subsequent grouping of key elements of the COPD syndrome
into clinically meaningful and useful subgroups (phenotypes) can guide therapy more effectively. In conclusion,
we firmly believe that an early and correct diagnosis can influence positively the progress of the disease (lowering
the lung function impairment), decrease the risk of exacerbations, relieve symptoms and increase the patients’
quality of life leading also to a decrease in costs associated to the exacerbations and hospitalization of the patient.
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conditions which are currently not sufficiently preven-
ted, underdiagnosed and undertreated [1]. Among these,
Chronic Obstructive Pulmonary Disease (COPD) repre-
sents a real problem for public health [2]. At European
level the prevalence of COPD is approximately 4-7%,
with the males and the elderly most affected by this dis-
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According to a recent study in Italy, COPD affects ap-
proximately 3% of the general population, but this
prevalence increases with age and in males, such as it
reaches 20% in males over 60 years old [4].
The real prevalence of this disease within a population
can vary based on the instrument used to identify it, that
is according to whether respiratory symptoms, medical
diagnosis, or pulmonary function are utilized [5,6].
The health, social and economic impact of COPD -
the third leading cause of death in the United States - is
high. In 2010, the global cost associated with COPD in
the USA was 50 billion dollars, of which 20bn of indirectl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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increase in a way directly proportional to the severity of
the illness and to moderate and severe exacerbations, es-
pecially those requiring hospitalization. Each patient af-
fected by COPD globally cost in 2010 $1,681 if in stage I
GOLD, $5,037 if in stage II, and $10,812 if in stage III.
The percentage of costs associated with hospitalization
increases with the worsening of stages.
In Italy, contrary to the US data, the average annual
cost for each patient affected by COPD is 2,724€, out
of which 92% is represented by direct costs: in par-
ticular, 19.6% is represented by pharmacological ther-
apy, 59.1% by hospitalizations and 6% by instrumental
examinations [8].
Exacerbations are a significant part of the natural pro-
gression of COPD and are responsible for large portion
of deaths, further decline in respiratory function, worsen-
ing of the quality of life, and increase in hospitalizations.
The ECLIPSE study revealed that the COPD frequent
exacerbator phenotype (n. of moderate/severe exacerba-
tions/year ≥ 2) represents approximately 30% of all COPD
patients [9].
Hospitalizations are generally the consequence of se-
vere exacerbations of COPD, and have a greater impact
on health costs [10].
One of the latest pharmacoeconomic studies regarding
this aspect points out that for each patient that has two
or more exacerbations/year [11], reducing exacerbations
with an appropriate treatment means reducing hospitali-
zations and thus related costs.
The problem of under-diagnosis
Currently, COPD is diagnosed in later or very advanced
stages. In Italy the under-diagnosis of COPD oscillates
between 25 and 50% and the results of some epidemio-
logical surveys conducted in the Padania Delta and in
Pisa-Cascina (zones of Italy) confirm the international
observations in this respect [12].
In Spain, it has been observed that only 60% of pa-
tients with chronic respiratory symptoms go to a doctor
and only 45% of them are then directed to a spirometry
test [13].
Respiratory symptoms are often not felt or are under-
estimated by the patient, who considers his symptoms as
physiological consequences of age or smoking habits
[14,15]. As a consequence, the patient does not consult
his doctor until his symptoms are aggravated, mainly
due to exacerbations. Also the general practitioner (GP)
can underestimate the situation in these occurrences, dia-
gnosing the episode only as an acute event rather than an
epiphenomenon of an unrecognized chronic problem,
thus neglecting to look further into the clinical history.
The result is that up to 80% of subjects affected with air-
ways obstruction, according to the GOLD spirometriccriteria, has never had a diagnosis of COPD, and even
among those with severe obstruction fewer than half
have already been diagnosed [16]. A missed diagnosis
influences the timing of therapeutic intervention, thus
contributing to the evolution into more severe stages of
the illness.
A late diagnosis may recognize many causes, of which
the most important are:
1) poor implementation of screening programs in
young smokers (40 to 55 years old)
2) little use of the GOLD or other questionnaires on a
general medicine level
3) not enough use of the spirometry both at general
medicine and pulmonologist level
4) low perception of symptoms in the initial phases of
the sickness.
Given the above mentioned epidemiological data, an in-
cisive intervention to limit under-diagnosis cannot act only
in remittance (passive diagnosis), but must act as the pro-
moter for a series of preventive actions: primary, secondary
and rehabilitative. For this reason, the “Schema di piano
sanitario nazionale 2011-2013” (National Health Plan
2011-2013) [17] establishes that the approach to managing
chronic respiratory illnesses, able to reconcile optimal
health assistance with sustainable public spending, is repre-
sented by “primary prevention and diagnosis as early as
possible, with standardized instruments, followed by ap-
propriate and timely therapies, able to prevent or delay in-
validity, treating those with chronic illnesses in their own
territory as much as possible”. The document, therefore,
aims at the precocity of diagnosis rather than at the pro-
motion of informative and educational interventions
against the main causes, such as smoking, or activation of
programs to reduce environmental and professional risks.
To reduce under-diagnosis, some actions need to be
taken:
1) Screening programs for at-risk subjects: smokers
In a setting of Swedish general practitioners, 27% of
smokers aged between 40 and 55 years, showed
bronchial obstruction (85% mild form, 13% moderate
form and 2% severe form) [18]. Similar results were
seen in Spain [19] and Holland [20]. More recently, a
screening program in Germany, conducted on
smokers aged between 40 and 60 years, identified 19%
with COPD in GOLD stage I [21].
It has been shown that a minimal anti-smoking
educational approach reduces the percentage of
smokers from 24% to 16% [22].
2) Use of the GOLD questionnaire
The use of the GOLD questionnaire appears to be
very helpful at the general medicine level.
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Respiratory Group, the systematic use of the
GOLD questionnaire at the general medicine level
allows for early identification of the stages of the
illness [23].
3) Spirometry
The use of spirometry in smokers, or those exposed
to atmospheric and/or environmental pollutants,
who show productive cough and dyspnea, allows for
early identification of the illness.
Early diagnosis
Early diagnosis is important as it allows for immediate
action against the causes of the illness (mostly smoking)
so that the progression of the respiratory pathology to-
wards more severe and invalidating levels can be delayed
or stopped [20,24].
Smoking cessation and long-term oxygen therapy in
the advanced phases of the illness represent the only
therapeutic measures proved effective in modifying the
natural progression of COPD and improving the survival
rates [25]. Furthermore, pharmacological therapy and re-
habilitation reduce the risk of exacerbations and improve
the quality of life [24]. An early start to treatment reduces
the effects of the illness on quality of life and the risk of
depression following diagnosis. As these psychological
factors influence patients’ adherence to therapy as well
as their quality of life, the doctor should know how to
recognize and diagnose them [26].
Early diagnosis is responsibility of GP, who should un-
derstand the dimensions of the problems caused by respi-
ratory diseases and in particular by COPD. For example, a
common practice should be to record the smoking habit
of each patient in the clinical file as well as the presence/
absence of cough, catarrh, or dyspnea. For each patient
who is a heavy smoker (pack/year > 15 is considered to be
at risk) or who has such symptoms, a spirometry should
be facilitated and strongly advised.
In this regard, a document jointly published by the
Italian Respiratory Societies together with a GP’s Society
and endorsed by the Italian Health Ministry [27], recom-
mends that all at-risk subjects undergo a simple spirom-
etry, while those with respiratory symptoms be examined
with global spirometry.
From clinical suspicion to diagnosis: screening of at-risk
subjects
There is a consensus regarding diagnoses based on
“screening of at-risk subjects”, rather than screening of
the general population. The latter would not be cost ef-
fective, due to the fact that the prevalence of COPD
cases remains modest among the general population,
while it is decisively higher in the group of smokers over
40 years of age.This approach is advised by the World Health Organi-
zation (WHO) in its document on the Global Alliance
for Respiratory Disorders (GARD), which suggests a
spirometry for each at-risk individual [28].
In practice, this means that all individuals over 40
years of age with risk factors should undergo a spirom-
etry test. Besides smoking, by far the most important
cause of COPD, professional exposure to dust particles
and other inhalable noxious substances for the respira-
tory apparatus should be considered, as well as atmos-
pheric pollution, and not only for those who live in big
cities.
What are then the factors that hinder the screening in
at-risk subjects?
The current waiting lists for respiratory function tests,
which in many regions are no longer than 5-6 weeks, do
not seem to represent the critical factor for the delay in
diagnosis or under-diagnosis of COPD, nor does the dis-
tance of the patients from specialized centers. COPD
develops over many years and decades and, therefore,
there is not an “urgency” for an evaluation but rather a
cogency for the evaluation to be done. In other words, it
is not important for the spirometry to be done from one
day to the next, but it is important that it is done. In this
regard, the relative brevity of the waiting list for the spir-
ometry is an indirect index of under-diagnosis of a path-
ology with a high prevalence. In medical groups, one
could foresee the execution of spirometry in doctor’s of-
fices with qualified hospital personnel to control the
quality of the tests, and even utilizing sponsorships from
associations and private individuals.
On the other hand, there seems to be the need for a
better awareness of the problems concerning chronic
respiratory diseases, and in particular COPD, and how
they will worsen in our society in the medium term.
The “COPD problem” needs to be put on the agenda
for healthcare planning at a central, regional and local
level, with integrated and targeted actions.
In this scenario, where early diagnosis of COPD is a
shared objective at all levels, we can hypothesize various
approaches.
Screening actions on a national scale can be translated
into the compilation of questionnaires in waiting rooms
of doctor’s offices or in pharmacies, in order to find risk
factors such as smoking habits, coughs, sputum or dys-
pnea [29]. Pharmacies should also play a facilitating role
in early diagnosis: similarly to the measurements of gly-
cemia, blood pressure and other blood chemistry, all easily
available, a measurement of FEV1 could be done simply
and quickly, with a subsequent notification to the GP.
If there was more awareness of the “COPD problem”,
a preventive campaign aimed at heavy smokers, with an
invitation to undergo a spirometry and clinical evalu-
ation every three-five years could be foreseen, much like
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is commonly accepted by the population for the screen-
ing of certain types of tumors.
In general, mass communication instruments (for ex-
ample commercials) could launch a campaign to sensitize
the public regarding respiratory problems.
After the COPD diagnosis
The first phases of the disease and the less complicated
cases should be the prerogative of the general practi-
tioner, who, therefore, becomes the pin around which
the initial diagnosis and therapies rotate. The paucisymp-
tomatic patient, with little obstruction at spirometry, with
rare or no exacerbations, especially if motivated and
aware, should be managed at the primary care level.
Smoking cessation, prevention of exacerbations with
vaccinations, adequate lifestyle (for example maintain-
ing or starting regular physical activity), and pharmaco-
logical therapy with bronchodilators, where needed or
continuously, are key to this management. In less severe
cases (stage I or stage A GOLD) the follow up could be
every year, with a repetition of the spirometry associated
with a clinical re-evaluation.
The patients with more advanced forms of the illness,
both from a functional and symptomatic standpoint,
those troubled with comorbidity (ex. cardiovascular), or
those patients with respiratory insufficiency or frequent
exacerbations, should be referred to the pulmonologist.
It seems, therefore, evident that what above described
represents a management model with several funda-
mental characteristics: a sharing of the progression of
the patient, a close contact between GP and pulmonolo-
gist, an educational approach and, where possible, a set-
ting of self-management by the patient, along with a
well-thought out, gradual and therefore cost efficient use
of healthcare resources.
COPD: a complex of multiple disorders
The call for the development of a new taxonomy for the
disorders of airflow obstruction has originated from the
recognition that asthma and COPD are not a single dis-
ease, but rather syndromes including multiple separate
disorders. A better understanding of the distinct disor-
ders of airways disease has the potential to inform on
underlying mechanisms, risk factors natural history,
monitoring and most importantly, treatment. The his-
tory of the guidelines of treatment of COPD is an ex-
ample of the simplification of a complex disease. The
Venn diagram included in the 1995 American Thoracic
Society statement for the management of COPD [30]
reflected the complexity of the disease and its different
clinical presentation. The limited alternatives for phar-
macological treatment at that time made it unnecessary
to identify the different types of patients for clinicalpractice. The evolution of the concept of one-treatment-
fits-all led to the selection of pharmacological treatment
based almost exclusively on the severity of airflow ob-
struction introduced in the first GOLD documents.
The diagnosis, assessment and management of COPD
are currently facing an important dilemma. On the one
hand, COPD is defined by the presence of airflow limita-
tion that is not fully reversible, and its treatment is
mostly guided by the severity of this limitation. On the
other hand, it is now widely recognized that COPD is a
complex syndrome with numerous several pulmonary
and extrapulmonary components. Importantly, signifi-
cant heterogeneity exists with respect to clinical presen-
tation, physiology, imaging, response to therapy, decline
in lung function, and survival. As a result, there is con-
sensus that airways obstruction as assessed by FEV1 by
itself does not adequately describe the complexity of
the disease and that FEV1 cannot be used alone for the
optimal diagnosis, assessment, and management of the
disease [31].
The recent revision of the GOLD initiative has moved
forward and changed the paradigm proposing a treat-
ment directed by the intensity of symptoms, measured
by the modified medical research council dyspnea scale
and/or the COPD assessment Test, and the risk of poor
outcomes, identified by the degree of airflow obstruction
and/or the frequency of exacerbations [32].What do we mean by “COPD phenotype”?
The identification and subsequent grouping of key ele-
ments of the COPD syndrome into clinically meaningful
and useful subgroups (phenotypes) that can guide therapy
more effectively is a potential solution of the dilemma.
A group of expert recently proposed the following
variation on the traditional definition of a phenotype: “a
single or a combination of disease attributes that describe
differences between individuals with COPD as they relate
to clinically meaningful outcomes (symptoms, exacerba-
tions, response to therapy, rate of disease progression, or
death)” [33].
In other words, it is proposed that phenotypes in
COPD should have real predictive value. The phenotype
should be able to classify patients into subgroups with
prognostic value and to determine the most appropriate
therapy to achieve better results from a clinical stand-
point. Many studies have attempted to identify and quan-
tify the prevalence of different phenotypes of COPD using
populations of various source and severity. There is still
no consensus on the number and definition of different
COPD phenotypes. There must be a compromise between
the oversimplification of the term COPD as a definition
that encompasses the entire spectrum of patients with in-
completely reversible airflow obstruction largely caused by
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individually as an orphan disease [34].
Phenotypes of clinical interest in COPD
According to the responses to pharmacological treat-
ment, the recent Spanish guidelines for the treatment of
COPD [35] have proposed four different phenotypes char-
acterized by the classical types of emphysema, chronic
bronchitis, exacerbators and patients with overlap COPD-
asthma. The proposed phenotypes in Guia Espanola de
la EPOC are as follows: 1) infrequent exacerbator with
either chronic bronchitis or emphysema; 2) overlap COPD-
asthma; 3) frequent exacerbator with predominant emphy-
sema; 3) frequent exacerbator with predominant chronic
bronchitis.
The overlap COPD-asthma phenotype is associated
with enhanced response to inhaled corticosteroids due
to the predominance of eosinophilic bronchial inflam-
mation [36]. The Spanish guidelines have also recognised
this phenotype and a consensus document has been gen-
erated with diagnostic criteria to identify patients with
overlap COPD asthma [37]. Among these criteria, the
most important are the history of previous asthma before
the age of 40 years, the demonstration of eosinophilic in-
flammation in sputum or increased peripheral eosino-
philia, and enhanced reversibility in airflow obstruction
after the bronchodilator test. Only 20% of overall patients
with respiratory obstructive diseases (i.e. COPD plus
asthma) over 64 years old belong to this category where a
combined therapy may be beneficial [38].
Looking closer to the prevalence of these different
phenotypes, it crystallizes that the majority of the pa-
tients belong to the group “infrequent exacerbator with
either chronic bronchitis or emphysema”. In this regard,
the observational ECLIPSE study, lasted 3 years, with
over 2,000 patients enrolled, provided substantial data to
demonstrate that the vast majority (70%) of the patients
with moderate-to-very severe COPD had less than 2 ex-
acerbations per year [9]. Of note, this study excluded
mild COPD patients: therefore, it is possible to assume
that among mild patients the percentage of infrequent
exacerbators is even higher. The cornerstone of the ther-
apy for these patients are long-acting bronchodilators as
also recommended by international guidelines. Accor-
ding to the same study, 30% of the moderate-to-very
severe patients are frequent exacerbators where, in
addition to the bronchodilation therapy, inhaled corti-
costeroids are recommended.
Evaluation of comorbidities
The cardiovascular comorbidities, such as ischemic car-
diac disease, systemic hypertension, hearth failure, stroke,
pulmonary hypertension are the most important in
terms of prevalence, prognosis and mortality and havein common with COPD the risk factors and the age.
Ageing of the population, in fact, increases the preva-
lence of chronic diseases, including cardiovascular and
pulmonary diseases, cancer and metabolic syndrome.
Almost half of all elderly people (> 65 yrs) have at least
three chronic medical conditions and one fifth have five
or more [39]. But the most relevant consideration about
the comorbidities is that they affect health outcomes in
COPD. Patients with COPD mainly die of non respira-
tory diseases such as cardiovascular diseases (25-27%),
cancer (mainly lung cancer 20-33%) and other causes
(30%) [40,41]. Respiratory failure due to COPD exacer-
bations accounts only for 4-35% of deaths.
Conclusions
This article deals with the prevalence and the reasons of
the underestimation of COPD in the population. Fur-
thermore, some suggestions were given on how to over-
come the obstacles to make the correct diagnosis in
order to provide the patients with the appropriate ther-
apy. We firmly believe that an early and correct diagno-
sis can positively influence the progress of the disease
(lowering the lung function impairment), decrease the
risk of exacerbations, relieve symptoms and increase the
quality of life of the patients leading also to a decrease in
the costs related to the exacerbations and hospitalization
of the patient.
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